AHA 2023 – Wegovy Cuts Death Risk, But Will That Be Enough For Payers?
The SELECT cardiovascular outcomes trial is a convincing hit; now Novo Nordisk must grapple with reimbursement and manufacturing.
The SELECT cardiovascular outcomes trial is a convincing hit; now Novo Nordisk must grapple with reimbursement and manufacturing.